Amicus Therapeutics (FOLD) to Release Quarterly Earnings on Wednesday

Amicus Therapeutics (NASDAQ:FOLD) is expected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $147.88 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Amicus Therapeutics Stock Up 0.8 %

Shares of NASDAQ FOLD opened at $9.85 on Wednesday. The firm has a market cap of $2.94 billion, a PE ratio of -28.97, a P/E/G ratio of 1.69 and a beta of 0.61. Amicus Therapeutics has a 12-month low of $8.78 and a 12-month high of $14.02. The company’s fifty day simple moving average is $9.60 and its 200 day simple moving average is $10.43. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Monday, January 13th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. StockNews.com raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, February 12th. Guggenheim increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.88.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.20% of the stock is currently owned by corporate insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.